Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03277365 · ClinicalTrials.gov registry record · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
A NA study of Heart Diseases, sponsored by Scripps Translational Science Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 100,000
- Enrollment target
- 1
- Study location
NCT03277365: Recruiting NA study of Heart Diseases, sponsored by Scripps Translational Science Institute.
NCT03277365 is a NA study of Heart Diseases that is actively recruiting participants, run by Scripps Translational Science Institute. The registered enrollment target is 100,000 participants, above the 4,356-participant average among 85 other Heart Diseases trials with a reported enrollment target (2196% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03277365, a NA study of Heart Diseases, is actively recruiting participants, sponsored by Scripps Translational Science Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 100,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Many conditions affecting health are caused by a combination of environment, behaviors, and genes. While individuals can alter some factors in their lives to reduce the chances of developing different diseases (e.g., not smoking cigarettes), the contribution from genetic risk encoded by DNA remains with people throughout their lives. Scientists are still trying to determine the entirety of genetic factors that influence disease, but for some conditions it has been shown that the factors identified thus far can begin to identify people at high to low genetic risk. Looking across the genome, scientists can calculate a cumulative genetic risk score - which can be used to rank genetic risk compared to other worldwide populations. The goal of this study is to determine how genetic risk influences health decisions and other things that can be controlled in life. The first genetic risk score is calculated for coronary heart disease (CAD). CAD ultimately leads to heart attacks, heart failure and sometimes sudden cardiac death and is the main reason heart disease remains as the number one cause of death worldwide. Other researchers have shown that this genetic risk score can be used to identify people with low, intermediate, and high risk for coronary heart disease. It has also been shown that the use of statins (cholesterol lowering drugs) provides greater benefit and protection against heart attack for people with high genetic risk for coronary artery disease. Leveraging the Apple ResearchKit and the ResearchKit linked 23andMe API, customers of 23andMe are able to provide researchers access to their genomic data. Participants will use the ResearchKit app to provide consent, view study information, answer surveys, and contact the study team. Participants will be asked to complete 3 surveys. One before viewing genetic risk scores, one immediately after viewing scores, and one 6 months after viewing scores.
Primary Outcome
Participant begins taking Statin as indicated by survey.
Conditions Studied
Interventions
- OTHER Receive genetic risk information
Study Locations (1)
California
- Scripps Translational Science Institute - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,000 participants |
| Start Date | 2017-09-26 |
| Est. Completion | 2030-09 |
| Phase | NA |
What NCT03277365 shows while recruiting
NCT03277365 is an interventional study that assigns participants to a tested intervention. Its 100,000 participants enrollment target places it among the larger protocols in the corpus, above the 4,356-participant average among 85 other Heart Diseases trials with a reported enrollment target (2196% higher).
The record links to 1 condition, with Heart Diseases appearing as the primary indexed condition, and to 1 intervention - of which Receive genetic risk information is the first listed.
NCT03277365 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03277365 about?
NCT03277365 is a clinical study titled "MyGeneRank: A Digital Platform for Next-Generation Genetic Studies". Many conditions affecting health are caused by a combination of environment, behaviors, and genes. While individuals can alter some factors in their lives to reduce the chances of developing different diseases (e.g., not smoking cigarettes), the contribution from genetic risk encoded by DNA remains ...
What is the current status of trial NCT03277365?
This trial is currently recruiting. It is a NA study. The enrollment target is 100,000 participants. The study started on 2017-09-26. Estimated completion is 2030-09.
What conditions does trial NCT03277365 study?
This clinical trial studies the following conditions: Heart Diseases.
What interventions are being tested in trial NCT03277365?
The interventions under investigation include: Receive genetic risk information (OTHER).
Who is sponsoring clinical trial NCT03277365?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03277365 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03277365's enrollment target sits among peer trials
100,000 2nd of 85 the highest of 85 other Heart Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Angiography and Electrogram Guided Bachmann Bundle Pacing
RECRUITING · NA
-
Understanding Decentralized Trial Engagement and Clinical Impediments Through Digital Efforts (UDECIDE) Among Unrepresented Groups With Poor Cardiovascular and Cardiometabolic Health
RECRUITING · NA
-
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
RECRUITING · NA
-
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR
RECRUITING · NA
-
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
RECRUITING · NA
-
Use of Bedside Imaging and Community Health Workers for Early Screening and Referral of Pre-symptomatic Stage B Heart Failure in the Emergency Department
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
- NCT04869111 · 100,000 participants · NA
The BrainHealth Project
- NCT05915299 · 100,000 participants
US National OCS Heart Perfusion (OHP) Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI